|
US4271068A
(en)
|
1968-05-10 |
1981-06-02 |
Ciba-Geigy Corporation |
Process for the manufacture of cystine-containing peptides
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4033940A
(en)
|
1975-11-12 |
1977-07-05 |
Armour Pharmaceutical Company |
Cyclization of peptides
|
|
US4216141A
(en)
|
1978-07-19 |
1980-08-05 |
The Salk Institute For Biological Studies |
Method for cyclization of peptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
NZ199722A
(en)
|
1981-02-25 |
1985-12-13 |
Genentech Inc |
Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US5371109A
(en)
|
1986-07-01 |
1994-12-06 |
Drilletten Ab |
Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
JP3127158B2
(ja)
|
1989-10-05 |
2001-01-22 |
オプテイン，インコーポレイティド |
新規の遺伝子及びポリペチドの無細胞合成並びに単離
|
|
US5585353A
(en)
|
1990-02-02 |
1996-12-17 |
The Rockefeller University |
Antibiotic peptides containing D-amino acids
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US5766897A
(en)
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
|
US5843701A
(en)
|
1990-08-02 |
1998-12-01 |
Nexstar Pharmaceticals, Inc. |
Systematic polypeptide evolution by reverse translation
|
|
US5270170A
(en)
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
|
DK0617706T3
(da)
|
1991-11-25 |
2001-11-12 |
Enzon Inc |
Multivalente antigenbindende proteiner
|
|
AU684510B2
(en)
|
1993-05-28 |
1997-12-18 |
Chiron Corporation |
Method for selection of biologically active peptide sequences
|
|
DK0710243T3
(da)
|
1993-06-29 |
2000-10-16 |
Ferring Bv |
Syntese af cykliske peptider
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
US5834318A
(en)
|
1995-05-10 |
1998-11-10 |
Bayer Corporation |
Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
|
|
US5912014A
(en)
|
1996-03-15 |
1999-06-15 |
Unigene Laboratories, Inc. |
Oral salmon calcitonin pharmaceutical products
|
|
US6720472B2
(en)
|
1996-07-12 |
2004-04-13 |
University Of Medicine And Dentistry Of New Jersey |
HMGI proteins in cancer and obesity
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6348584B1
(en)
|
1996-10-17 |
2002-02-19 |
John Edward Hodgson |
Fibronectin binding protein compounds
|
|
WO1998016636A1
(en)
|
1996-10-17 |
1998-04-23 |
Mitsubishi Chemical Corporation |
Molecule that homologizes genotype and phenotype and utilization thereof
|
|
US5922680A
(en)
|
1996-10-23 |
1999-07-13 |
Ferring, B.V. |
Stabilized composition for oral administration of peptides
|
|
US6261804B1
(en)
|
1997-01-21 |
2001-07-17 |
The General Hospital Corporation |
Selection of proteins using RNA-protein fusions
|
|
PT1712623E
(pt)
|
1997-01-21 |
2011-12-21 |
Gen Hospital Corp |
Selecção de proteínas utilizando fusões de arn-proteína
|
|
US5990237A
(en)
|
1997-05-21 |
1999-11-23 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
|
|
CA2293632C
(en)
|
1997-06-12 |
2011-11-29 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
|
EP0896001A1
(en)
|
1997-08-08 |
1999-02-10 |
Daicel Chemical Industries, Ltd. |
Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
|
|
US6429301B1
(en)
|
1998-04-17 |
2002-08-06 |
Whitehead Institute For Biomedical Research |
Use of a ribozyme to join nucleic acids and peptides
|
|
DE69931930T2
(de)
|
1998-08-07 |
2006-10-05 |
Emisphere Technologies, Inc. |
Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
|
|
WO2000021559A2
(en)
|
1998-10-09 |
2000-04-20 |
Musc Foundation For Research Development |
Blocking factor b to treat complement-mediated immune disease
|
|
US6962781B1
(en)
|
2000-05-19 |
2005-11-08 |
Proteonova, Inc. |
In vitro evolution of nucleic acids and encoded polypeptide
|
|
US7244701B2
(en)
|
2000-06-16 |
2007-07-17 |
Zealand Phama A/S |
Diuretic peptide conjugate
|
|
CN102258784A
(zh)
|
2003-05-15 |
2011-11-30 |
唐纳士公司 |
用于预防和治疗败血症的方法与组合物
|
|
EP1667702A2
(en)
|
2003-09-10 |
2006-06-14 |
Baxter International Inc., Baxter Healthcare Corp. |
Peptides that inhibit complement activation
|
|
JP4994039B2
(ja)
|
2003-11-26 |
2012-08-08 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
脂溶性または疎水性化合物の送達に有用なミセル系
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
US8951522B2
(en)
|
2011-04-08 |
2015-02-10 |
University Of Leicester |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
WO2006066258A2
(en)
|
2004-12-17 |
2006-06-22 |
Neose Technologies, Inc. |
Lipoconjugation of peptides
|
|
PL1844337T3
(pl)
|
2005-01-24 |
2013-12-31 |
Pepscan Systems Bv |
Związki wiążące, związki immunogenne i peptydomimetyki
|
|
US20060270590A1
(en)
|
2005-03-29 |
2006-11-30 |
Lockwood Samuel F |
Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
|
|
ES2548700T3
(es)
|
2005-05-26 |
2015-10-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
|
|
JP5198261B2
(ja)
|
2005-06-06 |
2013-05-15 |
カムルス エービー |
Ｇｌｐ−１類似体製剤
|
|
KR20150055628A
(ko)
|
2005-11-04 |
2015-05-21 |
제넨테크, 인크. |
안질환 치료를 위한 보체 경로 억제제의 용도
|
|
BR122017024057B8
(pt)
*
|
2006-03-15 |
2021-05-25 |
Alexion Pharma Inc |
anticorpo que se liga à c5 e composição farmacêutica compreendendo dito anticorpo e um veículo farmaceuticamente aceitável
|
|
EP1876183A1
(en)
|
2006-07-04 |
2008-01-09 |
Technische Universität München |
Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
|
|
DK3028716T3
(da)
|
2006-10-10 |
2020-11-23 |
Regenesance B V |
Komplementhæmning til forbedret nerveregeneration
|
|
US7736860B2
(en)
|
2006-11-09 |
2010-06-15 |
Univeristy Of Massachusetts |
Methods of identifying compounds for the treatment of sterile inflammation
|
|
US20100166748A1
(en)
|
2007-03-22 |
2010-07-01 |
Novartis Ag |
C5 Antigens and Uses Thereof
|
|
US20100015139A1
(en)
|
2008-07-10 |
2010-01-21 |
Rekha Bansal |
METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
|
|
BRPI0811007A2
(pt)
|
2007-04-30 |
2015-01-27 |
Alcon Res Ltd |
Tratamento de degeneração macular relacionada à idade usando inibidores de fator de complemento d
|
|
BRPI0812767A2
(pt)
|
2007-06-07 |
2014-12-02 |
Genentech Inc |
Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
|
|
US20110142837A1
(en)
|
2007-07-20 |
2011-06-16 |
Trustees Of The University Of Pennsylvania |
Method Of Treating Acute Respiratory Distress Syndrome
|
|
KR20100094453A
(ko)
|
2007-10-02 |
2010-08-26 |
포텐시아 팔마큐티칼스, 인크. |
겔로부터 콤스타틴 유사체의 지속적 운반
|
|
WO2009067191A2
(en)
|
2007-11-16 |
2009-05-28 |
The General Hospital Corporation |
Methods and compositions for the treatment of hepatitis c virus (hcv) infection
|
|
EP2278987A4
(en)
|
2008-03-28 |
2012-08-22 |
Apellis Ag |
MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
|
|
EP2324048A2
(en)
|
2008-07-30 |
2011-05-25 |
Cosmix Therapeutics Llc |
Peptide therapeutics that bind vegf and methods of use thereof
|
|
AU2009290137A1
(en)
|
2008-09-03 |
2010-03-11 |
Xenome Ltd |
Libraries of peptide conjugates and methods for making them
|
|
FI2894165T3
(fi)
|
2008-11-10 |
2023-03-23 |
Alexion Pharma Inc |
Menetelmiä ja koostumuksia komplementtiin liityvien häiriöiden hoitamiseksi
|
|
AU2009230735B1
(en)
|
2009-01-08 |
2010-01-21 |
Shane Ramodien |
Electronic equipment housing
|
|
CA2777845C
(en)
|
2009-10-16 |
2017-08-01 |
Omeros Corporation |
Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
|
|
NZ600393A
(en)
|
2009-11-05 |
2014-08-29 |
Alexion Cambridge Corp |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
|
WO2011073328A1
(en)
|
2009-12-16 |
2011-06-23 |
Novo Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
|
US9358266B2
(en)
|
2010-02-25 |
2016-06-07 |
The Trustees Of The University Of Pennsylvania |
Treatment of sepsis using complement inhibitors
|
|
US20110269807A1
(en)
|
2010-04-30 |
2011-11-03 |
Allergan, Inc. |
Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
|
|
TW201241008A
(en)
*
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
|
CA2831563A1
(en)
*
|
2011-03-29 |
2012-10-04 |
Abbvie Inc. |
Improved shroud deployment in automatic injection devices
|
|
RU2639521C2
(ru)
*
|
2011-05-05 |
2017-12-21 |
ВЕЛЛСТАТ ИММЬЮНОТЕРАПЬЮТИКС, ЭлЭлСи |
Аналоги фактора комплемента в и их применения
|
|
WO2012162215A1
(en)
|
2011-05-20 |
2012-11-29 |
The Trustees Of The University Of Pennsylvania |
Promotion of fracture healing using complement inhibitors
|
|
WO2012174055A1
(en)
|
2011-06-13 |
2012-12-20 |
The Trustees Of The University Of Pennsylvania |
Wound healing using complement inhibitors
|
|
CN102321170B
(zh)
|
2011-09-14 |
2013-11-13 |
深圳翰宇药业股份有限公司 |
利拉鲁肽变构体及其缀合物
|
|
WO2013052736A2
(en)
|
2011-10-06 |
2013-04-11 |
The Medicines Company |
Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
|
|
SMT201900189T1
(it)
|
2012-02-20 |
2019-05-10 |
Swedish Orphan Biovitrum Ab Publ |
Polipeptidi che si legano al c5 del complemento umano
|
|
US20130246083A1
(en)
|
2012-03-16 |
2013-09-19 |
Alexion Pharmaceuticals, Inc. |
Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
|
|
EP2850095B1
(en)
|
2012-05-17 |
2019-10-09 |
RA Pharmaceuticals, Inc. |
Peptide and peptidomimetic inhibitors
|
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
WO2014004733A1
(en)
|
2012-06-26 |
2014-01-03 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
WO2014078622A1
(en)
|
2012-11-15 |
2014-05-22 |
The Brigham And Women's Hospital, Inc. |
Method and system for diagnosing and treating preeclampsia
|
|
US9700633B2
(en)
|
2013-01-28 |
2017-07-11 |
Jenkem Technology Co., Ltd., Tianjin Branch |
Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
|
|
US20140234275A1
(en)
|
2013-02-15 |
2014-08-21 |
Jason Williams |
Method for treating als via the increased production of factor h
|
|
US20150057342A1
(en)
|
2013-08-21 |
2015-02-26 |
Cannabics Pharmaceuticals Inc |
Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
|
|
CN104231085B
(zh)
*
|
2013-09-05 |
2017-03-15 |
复旦大学附属肿瘤医院 |
靶向特异性补体系统抑制剂、其制备方法及应用
|
|
MX2016011862A
(es)
|
2014-03-20 |
2016-12-05 |
Inflarx Gmbh |
Inhibidores de c5a para el tratamiento de la neumonia viral.
|
|
JP6432954B2
(ja)
*
|
2014-06-12 |
2018-12-05 |
ラ ファーマシューティカルズ インコーポレイテッドＲａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
補体活性の変調
|
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
|
CN107427482A
(zh)
|
2015-01-21 |
2017-12-01 |
帕西拉制药有限公司 |
凝血酸的多囊脂质体制剂
|
|
SI3250230T1
(sl)
*
|
2015-01-28 |
2022-01-31 |
Ra Pharmaceuticals, Inc. |
Modulatorji aktivnosti komplementa
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
AU2016370210A1
(en)
*
|
2015-12-16 |
2018-06-21 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
|
JP7301741B2
(ja)
*
|
2016-12-07 |
2023-07-03 |
ラ ファーマシューティカルズ インコーポレイテッド |
補体活性のモジュレータ
|
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
|
EP3682016A4
(en)
|
2017-09-11 |
2021-06-02 |
RA Pharmaceuticals, Inc. |
FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
|
|
MX2020005547A
(es)
|
2017-12-04 |
2020-08-20 |
Ra Pharmaceuticals Inc |
Moduladores de la actividad del complemento.
|
|
CN113543796A
(zh)
|
2019-03-08 |
2021-10-22 |
Ra制药公司 |
齐鲁考普作为深层组织穿透性c5抑制剂
|
|
US20220211799A1
(en)
|
2019-04-24 |
2022-07-07 |
Ra Pharmaceuticals, Inc. |
Compositions and methods for modulating complement activity
|